生脉注射液联合格列美脲治疗气阴两虚型2型糖尿病的临床疗效及对患者血清炎性因子的影响  

Efficacy of Shengmai Injection Combined with Glimepiride in Treatment of Type 2 Diabetes Mellitus and Effect on Inflammatory Factor in Serum

作　　者：马锐 吴胜本[2] 毛静远[3] 

机构地区：[1]滨州市中医医院,山东滨州256613 [2]滨州市人民医院,山东滨州256600 [3]天津中医药大学第一附属医院,天津300193

出　　处：《中国实验方剂学杂志》2016年第4期150-153,共4页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：国家自然科学基金项目(90709037)

摘　　要：目的:探讨生脉注射液联合格列美脲治疗气阴两虚型2型糖尿病的临床效果及对血清炎性因子的影响。方法:选取2013年2月—2015年2月来滨州市中医医院就诊的2型糖尿病患者152例,采用随机数字法分为观察组77例和对照组75例。对照组给予格列美脲进行治疗,观察组在对照组治疗的基础上联合生脉注射液治疗。观察比较两组患者的临床有效率,空腹血糖(FBG),餐后2 h血糖(2 h PBG),糖化血红蛋白(Hb A1c)的改变及血清高敏C反应蛋白(hs-CRP),肿瘤坏死因子-α(TNF-α),白细胞介素-1β(IL^(-1)β)水平变化及不良反应情况。结果:观察组总有效率92.21%,明显高于对照组的78.67%(P<0.05)。两组FBG[(5.87±0.32)VS(10.63±0.53)mmol·L^(-1)],2 h PBG[(6.52±1.22)VS(11.24±2.72)mmol·L^(-1)],Hb A1c[(4.42±0.37)%VS(6.21±0.52)%]比较,观察组明显低于对照组(P<0.05)。治疗后,两组患者的hs-CRP,TNF-α,IL^(-1)β水平显著降低(P<0.05),且两组hs-CRP[(2.25±0.73)VS(3.37±1.01)g·L^(-1)],TNF-α[(1.56±0.47)VS(2.23±0.44)ng·L^(-1)],IL^(-1)β[(15.36±3.70)VS(22.94±3.81)ng·L^(-1)]比较,观察组水平明显低于对照组(P<0.05)。两组患者治疗期间不良反应主要为呕吐、腹泻和低血糖,经对症治疗后均痊愈,不良反应发生率比较差异无统计学意义。结论:生脉注射液联合格列美脲治疗气阴两虚型2型糖尿病的疗效明显,同时可降低患者体内炎性因子的水平,从而可能延缓气阴两虚型2型糖尿病并发症的发生,值得临床推广使用。Objective ： To investigate the clinical effect of Shengmai injection in the treatment of type 2 diabetes mellitus with Qi and Yin deficiency and its effect combined with glimepiride on inflammatory factors in serum. Method： Totally 152 patients with type 2 diabetes mellitus in our hospital during February 2013 to February 2015 were randomly divided into observation group （n = 77） and control group （n = 75）. The patients in control group were treated with glimepiride therapy, while the patients in observation group were treated by Shengmai injection on the basis of glimepiride. The clinical efficiency, changes of fasting blood glucose （FBG） , postprandial 2 h blood glucose （2 h PBG） , and glycosylated hemoglobin （HbAlc） , changes in high-sensitivity c- reactive protein （hs-CRP）, tumor necrosis factor alpha （TNF-α）, and interleukin-1 beta （IL-1β）, as well as side effects between two groups were compared. Result： The total clinical effective rate was 92.21% in observation group, significantly higher than 78.67% in control group, with statistically significant difference between two groups （P〈0.05）. FBG, 2hPBG, and HbAlc were （5.87±0.32）, （6.52±-1.22） mmol.L-1, and （4.42± 0.37） % respectively in observation group, significantly lower than （ 10. 63± 0. 53）, （ 11.24 ± 2. 72） mmol ·L-1, and （6.21 ± 0.52） % in control group, with statistical difference （P 〈 0.05）. After treatment, hs-CRP, TNF-α and IL-1β levels were significantly decreased in both groups （P 〈 0.05） , and hs-CRP, TNF-α and IL-1β levels were （2.25 ±0.73） g ·L-1, （1.56 ±0.47） ng·L-1, and （15.36 ± 3.70） ng·L-1in observation group, significantly lower than （3.37± 1.01 ） g·L-1, （2.23± 0.44） ng·L-1, and （22.94 ± 3.81 ） ng ·L-1 in control group, with statistical difference （P 〈 0.05）. The adverse reactions mainly included vomiting, diarrhea, and low blood sugar during treatment in two groups, and it was recovered after symptomati

关 键 词：生脉注射液 格列美脲 2型糖尿病 糖化血红蛋白 白细胞介素-1Β 

分 类 号：R287.6[医药卫生—中药学]